Aarohan Pruthi Clinical Oncology Society of Australia Annual Scientific Meeting 2026

Abstracts this author is presenting:

• Olomorasib and immunotherapy in stage II-III KRAS G12C-mutant NSCLC after definitive therapy: SUNRAY-02 study rationale — Thursday Poster Session
• Final update for safety and efficacy of selpercatinib in first line patients with RET-fusion positive thyroid cancer: data from LIBRETTO-001 — Thursday Poster Session
• Selpercatinib in pediatric and adolescent patients with RET-altered solid tumors: safety and efficacy results from the phase 1/2 LIBRETTO-121 study — Thursday Poster Session
• Event-free survival (EFS) with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive (RET+) NSCLC: primary results of the phase 3 LIBRETTO-432 trial — Thursday Poster Session
• First-line (1L) olomorasib + chemoimmunotherapy (chemo-IO) in KRAS G12C-mutant NSCLC: updated results from the LOXO-RAS-20001 and SUNRAY-01 trials — Thursday Poster Session
• First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: updated results from LOXO-RAS-20001 and SUNRAY-01     — Thursday Poster Session
• Intracranial efficacy of olomorasib, a next-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases   — Thursday Poster Session